$34 mil over the next 15 yrs in royalties, page-16

Posted this on the STT thread, may help a few to see the bigger picture,




Cash: $1.9 mill
Shares: 1.43 billion
MC: $23 mill

PERTH, AUSTRALIA SUDA LTD (ASX: SUD), a leader in oro-mucosal ( nasal spray ) drug delivery..


Earning money ? tick

Receipts from customers for the period were $1.6 million, an increase of 25% from the first quarter of FY2016.

Running a tight ship ? tick

The Company reduced its net operating cash loss to $0.25 million in the first quarter compared to $0.61 million in the previous corresponding period of FY2016

No CR in the distant future ? tick

"the Directors believe that the cash position is sufficient for 12 months in the absence of anticipated income from licensing deals."


SUDA’s CEO, Mr Stephen Carter, commented: “Our medical and surgical supplies subsidiary, Westcoast, is growing and making a positive contribution to our operating cash flow. We are delighted that receipts from customers are up 25% from the previous year. We have reduced our overall cash burn at an exciting time for the Company as we seek to finalise long-awaited licensing deals.”

From todays announcement:

leading Chinese pharmaceutical company, today announce that the companies have entered into an exclusive license agreement for the development and commercialisation of SUDA’s novel ZolpiMist™ oral spray of zolpidem tartrate to treat insomnia in China. Once approved by the Chinese Food and Drug Administration (CFDA), ZolpiMist would be the first imported fast-acting oral spray of zolpidem tartrate available in China. Under the terms of the agreement, SUDA receives an upfront cash payment of US$300,000 (approx. A$400,000) and is entitled to receive a further milestone payment of US$200,000 (approx. A$260,000) following registration of the product in China.

In addition, once Zolpimist is registered for sale in China, SUDA will receive escalating tiered royalties on net sales in the territory. The total value of the deal could exceed US$26 million (approx. A$34 million) based on Eddingpharm’s forecast sales for the first 15 years from launch. Under the terms of the agreement, Eddingpharm will assume responsibility for development, regulatory and commercialisation activities for ZolpiMist in China. SUDA will supply the product to Eddingpharm and both parties will work together through a Joint Governance Committee to maximise the commercial opportunity for ZolpiMist in China


Other works in the pipeline:




So we have a company that is taking already proven key ingredients in drug's & turning them into nasal spray's.. Half the work is already done here, but these two drugs in clinical stages give me a real stiffi

SUD-003 (DuroMist™) is a first-in-class oral spray formulation of *word disallowed by google (marketed in tablet form by Pfizer under the brand name Viagra®), sprayed directly in the mouth over the tongue for the treatment of erectile dysfunction (ED). The Duromist™ dosage form is a metered spray that offers the potential for increased patient convenience, reduced food effect and lower dose.

SUD-001 is a first-in-class mint-flavoured oral spray formulation of sumatriptan (marketed in tablet form and in a nasal spray by GlaxoSmithKline under the brand name Imitrex®). Sumatriptan is one of the most widely used drugs for the treatment of acute migraine in adults and works by narrowing the blood vessels in the brain.

If SUD can get into the Chinese market with one product.. Then when these two come out, SUD should be easy a Disallowed going into 2017


Edit: Buy/Held